CO5011096A1 - Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs - Google Patents

Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs

Info

Publication number
CO5011096A1
CO5011096A1 CO98057956A CO98057956A CO5011096A1 CO 5011096 A1 CO5011096 A1 CO 5011096A1 CO 98057956 A CO98057956 A CO 98057956A CO 98057956 A CO98057956 A CO 98057956A CO 5011096 A1 CO5011096 A1 CO 5011096A1
Authority
CO
Colombia
Prior art keywords
treatment
ibs
receptor
medicines containing
containing antagonists
Prior art date
Application number
CO98057956A
Other languages
English (en)
Inventor
Mangel Allen Wayne
Allison Ruth Northcutt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5011096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5011096A1 publication Critical patent/CO5011096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un antagonista del receptor de 5-HT3 o un derivado del mismoaceptable farmacéuticamente para el uso en la fabricación de un medicamento para el tratamiento de pacientes femeninos con IBS no constipados. Un antagonista del receptor de 5-HT3 o un derivado del mismo aceptable farmacéuticamente, para su uso en el tratamiento de pacientes femeninos con IBS no constipados.
CO98057956A 1997-10-07 1998-10-06 Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs CO5011096A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments

Publications (1)

Publication Number Publication Date
CO5011096A1 true CO5011096A1 (es) 2001-02-28

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98057956A CO5011096A1 (es) 1997-10-07 1998-10-06 Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs

Country Status (36)

Country Link
US (3) US6284770B1 (es)
EP (1) EP1021174A2 (es)
JP (1) JP2001518495A (es)
KR (1) KR20010015707A (es)
CN (1) CN1281357A (es)
AP (1) AP2000001785A0 (es)
AR (1) AR017296A1 (es)
AU (1) AU750818B2 (es)
BR (1) BR9812886A (es)
CA (1) CA2305751A1 (es)
CO (1) CO5011096A1 (es)
DZ (1) DZ2618A1 (es)
EA (1) EA003184B1 (es)
EE (1) EE200000214A (es)
GB (1) GB9721139D0 (es)
GT (1) GT199800157A (es)
HN (1) HN1998000155A (es)
HR (1) HRP20000198A2 (es)
HU (1) HUP0003750A3 (es)
ID (1) ID23874A (es)
IL (1) IL135398A0 (es)
IS (1) IS5425A (es)
MA (1) MA26549A1 (es)
NO (1) NO20001776L (es)
NZ (1) NZ503698A (es)
PA (1) PA8461101A1 (es)
PE (1) PE120299A1 (es)
PL (1) PL340337A1 (es)
SK (1) SK4862000A3 (es)
SV (1) SV1998000122A (es)
TN (1) TNSN98179A1 (es)
TR (1) TR200000913T2 (es)
UY (1) UY25200A1 (es)
WO (1) WO1999017755A2 (es)
YU (1) YU20600A (es)
ZA (1) ZA989061B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
AU2001288564A1 (en) * 2000-09-06 2002-03-22 Glaxo Group Limited 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
CA2449987C (en) * 2001-06-07 2015-11-03 Christine N. Sang Treatment of central neuropathic pain
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
CA2473392A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
DE60326585D1 (de) * 2002-07-10 2009-04-23 Dynogen Pharmaceuticals Inc 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidin bei der behandlung von funktionalen darmstörungen
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
AU2003252738A1 (en) * 2002-08-09 2004-02-25 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
MXPA05007379A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
CN100353946C (zh) * 2003-01-13 2007-12-12 戴诺吉药品有限公司 治疗功能性肠病的方法
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
JP2007514000A (ja) * 2003-12-16 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド テガセロッド塩基及びその塩の多形現象形
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
CA2516433C (en) * 2004-01-30 2009-06-02 Astellas Pharma Inc. Ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome
EP1718148A2 (en) * 2004-02-03 2006-11-08 The Regents of the University of California Methods of treating irritable bowel syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1724267B1 (en) 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
JP5086248B2 (ja) * 2005-06-07 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
MX2008010645A (es) * 2006-02-20 2008-10-14 Astellas Pharma Inc Derivado de amida o sal del mismo.
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
SG10201502453SA (en) 2009-03-04 2015-05-28 Liveleaf Inc Method and material for site activated complexing of biologic molecules
WO2010127132A1 (en) 2009-04-29 2010-11-04 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
WO2011001954A1 (ja) * 2009-06-30 2011-01-06 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US9358228B2 (en) * 2011-10-18 2016-06-07 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
EP2892514A4 (en) 2012-09-05 2016-04-13 Chase Pharmaceuticals Corp Neurotropic Anticholinergic Composition and Method
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3782107T2 (de) 1986-07-25 1993-04-01 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
DE3851597T2 (de) * 1987-09-03 1995-01-26 Glaxo Group Ltd Lactamderivate.
DE3850742T2 (de) 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
EP0336759A1 (en) * 1988-04-07 1989-10-11 Glaxo Group Limited Imidazole derivatives
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
WO1992012149A1 (en) * 1991-01-09 1992-07-23 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
US6284770B1 (en) 2001-09-04
BR9812886A (pt) 2000-08-08
IL135398A0 (en) 2001-05-20
AR017296A1 (es) 2001-09-05
CA2305751A1 (en) 1999-04-15
DZ2618A1 (fr) 2003-03-01
HN1998000155A (es) 1999-05-24
NZ503698A (en) 2002-10-25
SK4862000A3 (en) 2001-01-18
TNSN98179A1 (fr) 2005-03-15
WO1999017755A2 (en) 1999-04-15
GT199800157A (es) 2000-03-30
US20030036549A1 (en) 2003-02-20
PE120299A1 (es) 1999-12-15
EP1021174A2 (en) 2000-07-26
KR20010015707A (ko) 2001-02-26
EA200000299A1 (ru) 2000-12-25
JP2001518495A (ja) 2001-10-16
GB9721139D0 (en) 1997-12-03
PA8461101A1 (es) 2000-05-24
AP2000001785A0 (en) 2000-06-30
NO20001776L (no) 2000-06-06
ZA989061B (en) 2001-07-05
PL340337A1 (en) 2001-01-29
HUP0003750A2 (hu) 2001-10-28
AU9629398A (en) 1999-04-27
US20010044450A1 (en) 2001-11-22
WO1999017755A3 (en) 1999-09-23
US6429209B2 (en) 2002-08-06
AU750818B2 (en) 2002-07-25
EA003184B1 (ru) 2003-02-27
MA26549A1 (fr) 2004-12-20
YU20600A (sh) 2003-10-31
US6593336B2 (en) 2003-07-15
TR200000913T2 (tr) 2001-01-22
HRP20000198A2 (en) 2001-04-30
ID23874A (id) 2000-05-25
EE200000214A (et) 2001-06-15
CN1281357A (zh) 2001-01-24
IS5425A (is) 2000-03-31
NO20001776D0 (no) 2000-04-06
HUP0003750A3 (en) 2003-02-28
UY25200A1 (es) 2001-01-31
SV1998000122A (es) 1999-07-05

Similar Documents

Publication Publication Date Title
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
MX9203444A (es) Medicamentos.
NO20013469D0 (no) Fremgangsmåter for glukagonsuppresjon
EE200000320A (et) Uudsed ühendid
DK1036059T3 (da) Adamantanderivater
ATE524176T1 (de) Valsartan tablette
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
ES2125567T3 (es) Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
UY26376A1 (es) Combinaciones sinteticas de un antagonista de nk1 y un analogo estructural de gaba
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR029882A1 (es) Derivados de 3a,4,5,9b-tetrahidro-1h-benz[e]indol-2-il amina utiles en el tratamiento de la obesidad y otros desordenes, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento
BR0010092A (pt) Composto, preparação farmacêutica para a administração oral ou parenteral, uso de um composto, e, uso da preparação farmacêutica
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.